GURE:NASDAQGulf Resources, Inc. Analysis
Data as of 2026-05-19 - not real-time
$3.85
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Gulf Resources, Inc. (GURE) is trading at $3.85, well below its 20‑day SMA of 3.94 and the 50‑day SMA of 4.81, indicating a bearish price stance. The 14‑day RSI sits at 44, suggesting neutral momentum but no near‑term oversold condition. MACD shows a bullish crossover (‑0.34 line above ‑0.42 signal) with a small positive histogram, offering a faint technical upside. Volume is on a decreasing trend and the market cap is under $6 M, highlighting liquidity constraints. Volatility over the past 30 days is extreme at 149 %, and beta is low at 0.30, meaning price swings are large but not strongly correlated with the market. The DCF‑derived fair value of $87.92 versus the current price implies a massive valuation gap. The Fear & Greed Index reads Extreme Greed (88.98), reflecting market euphoria that may be overlooking the company’s fundamentals.
Fundamentally, GURE reports negative gross (‑28 %) and operating margins (‑4 %), a trailing EPS of ‑$49.34, and a max drawdown of ‑72 %, underscoring severe profitability issues. Debt‑to‑equity is high at 7.5 and free cash flow is deeply negative, raising solvency concerns. A recent NASDAQ notice for late filing of the annual report adds regulatory risk. With a price‑to‑book of only 0.05 and a PB ratio that is dramatically low, the stock appears deeply discounted but fraught with risk. The overall picture is one of a severely distressed company that is technically bearish, highly volatile, and facing liquidity and compliance challenges despite an apparent valuation upside.
Fundamentally, GURE reports negative gross (‑28 %) and operating margins (‑4 %), a trailing EPS of ‑$49.34, and a max drawdown of ‑72 %, underscoring severe profitability issues. Debt‑to‑equity is high at 7.5 and free cash flow is deeply negative, raising solvency concerns. A recent NASDAQ notice for late filing of the annual report adds regulatory risk. With a price‑to‑book of only 0.05 and a PB ratio that is dramatically low, the stock appears deeply discounted but fraught with risk. The overall picture is one of a severely distressed company that is technically bearish, highly volatile, and facing liquidity and compliance challenges despite an apparent valuation upside.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- price below short‑term moving averages
- decreasing volume and high volatility
- regulatory filing delinquency
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- massive DCF upside potential
- ongoing profitability and cash‑flow deficits
- uncertain debt restructuring outlook
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- extreme price discount to fair value
- potential industry demand for bromine and salt
- possibility of turnaround after financial restructuring
Key Metrics & Analysis
Financial Health
Revenue Growth303.40%
Profit Margin-286.76%
ROE-43.38%
ROA-4.60%
Debt/Equity7.50
P/B Ratio0.0
Op. Cash Flow$5.5M
Free Cash Flow$-12061764
Technical Analysis
TrendBearish
RSI44.0
Support$3.20
Resistance$5.69
MA 20$3.94
MA 50$4.81
MA 200$5.16
MACDBullish
VolumeDecreasing
Fear & Greed Index88.98
Valuation
Fair Value$87.92
GradeUndervalued
TypeValue
Risk Assessment
Beta0.30
Volatility149.39%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.